title: [Successful combination therapy with 5'-DFUR and MPA for breast cancer with spinal and vertebral metastases].
abstract: We report a case of breast cancer with spinal and vertebral lesions. A 49-year-old premenopausal woman with a left breast tumor was admitted to our hospital for acute weakness of the lower limbs and dysuria. She could neither stand nor walk. The tumor in the left breast was 5.0 cm in diameter with skin ulcer, and it was diagnosed as breast cancer. Magnetic resonance (MR) image showed multiple vertebral and spinal metastases from breast cancer. Chemotherapy, consisting of cyclophosphamide, doxorubicin and 5-fluorouracil (CAF) was initiated. Her symptoms dramatically changed for the better. She became able to walk and urinate. We performed palliative mastectomy after 3 cycles of CAF therapy. Histopathological findings of breast tumor showed scirrhous carcinoma. Although the estrogen and progesterone receptor status of primary tumor was negative, chemo-endocrine therapy, consisting of medroxyprogesterone acetate (MPA) and doxifluridine (5'-DFUR) was given as daily therapy, and vertebral and spinal lesions were reduced. Her condition has remained stable for 4 years. For patients with metastatic breast cancer, complete remission is uncommon, and disease stabilization is a reasonable goal of successful therapy. In this respect, therapy with CAF, followed by MPA and 5'-DFUR, was successful in the patient.
authors.affiliation: Division of Organ Surgical Oncology, Tottori University, Faculty of Medicine.
authors.forename: Shinji
authors.initials: S
authors.lastname: Otani
authors.forename: Nobuhiko
authors.initials: N
authors.lastname: Toyota
authors.forename: Kimiyasu
authors.initials: K
authors.lastname: Nozaka
authors.forename: Toshiro
authors.initials: T
authors.lastname: Wakatsuki
authors.forename: Masataka
authors.initials: M
authors.lastname: Takebayashi
authors.forename: Akira
authors.initials: A
authors.lastname: Kamasako
authors.forename: Osamu
authors.initials: O
authors.lastname: Tanida
authors.forename: Hirokazu
authors.initials: H
authors.lastname: Hashiguchi
authors.forename: Yoshimi
authors.initials: Y
authors.lastname: Ohgami
authors.forename: Yasuaki
authors.initials: Y
authors.lastname: Hirooka
mesh_terms: D002293:Adenocarcinoma, Scirrhous / Q000175:diagnosis / Q000188:drug therapy* / Q000556:secondary* / Q000601:surgery; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000175:diagnosis / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D004334:Drug Administration Schedule; D005260:Female; D005467:Floxuridine / Q000008:administration & dosage; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D008279:Magnetic Resonance Imaging; D008408:Mastectomy; D017258:Medroxyprogesterone Acetate / Q000008:administration & dosage; D008875:Middle Aged; D012074:Remission Induction; D013120:Spinal Cord Neoplasms / Q000175:diagnosis / Q000556:secondary*; D013125:Spinal Neoplasms / Q000175:diagnosis / Q000556:secondary*
chemical_list: D005467:Floxuridine; D004317:Doxorubicin; D003520:Cyclophosphamide; D017258:Medroxyprogesterone Acetate; D005472:Fluorouracil; C025034:doxifluridine